528 related articles for article (PubMed ID: 27900428)
1. Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials.
Mawatari T; Muraoka R; Iwamoto Y
Osteoporos Int; 2017 Apr; 28(4):1279-1286. PubMed ID: 27900428
[TBL] [Abstract][Full Text] [Related]
2. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
Palomba S; Orio F; Manguso F; Falbo A; Russo T; Tolino A; Tauchmanovà L; Colao A; Doldo P; Mastrantonio P; Zullo F
Osteoporos Int; 2005 Sep; 16(9):1141-9. PubMed ID: 15928801
[TBL] [Abstract][Full Text] [Related]
4. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
[TBL] [Abstract][Full Text] [Related]
5. Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study.
Nakano T; Yamamoto M; Hashimoto J; Tobinai M; Yoshida S; Nakamura T
J Bone Miner Metab; 2016 Nov; 34(6):678-684. PubMed ID: 26462480
[TBL] [Abstract][Full Text] [Related]
6. Eldecalcitol increases bone mineral density in Chinese osteoporotic patients without vitamin D or calcium supplementation.
Jiang Y; Tang H; Ma X; Cheng Q; Lin H; Jin X; Zhang Z; Yu W; He S; Kobayashi T; Uehara S; Matsumoto T; Xia W
J Bone Miner Metab; 2019 Nov; 37(6):1036-1047. PubMed ID: 31087185
[TBL] [Abstract][Full Text] [Related]
7. Role of vitamin D levels and vitamin D supplementation on bone mineral density in Klinefelter syndrome.
Ferlin A; Selice R; Di Mambro A; Ghezzi M; Di Nisio A; Caretta N; Foresta C
Osteoporos Int; 2015 Aug; 26(8):2193-202. PubMed ID: 25963234
[TBL] [Abstract][Full Text] [Related]
8. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ; Naganathan V; Barton I; Grauer A
J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
[TBL] [Abstract][Full Text] [Related]
10. Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.
Kanaji A; Higashi M; Namisato M; Nishio M; Ando K; Yamada H
Lepr Rev; 2006 Jun; 77(2):147-53. PubMed ID: 16895071
[TBL] [Abstract][Full Text] [Related]
11. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
Saag KG; Pannacciulli N; Geusens P; Adachi JD; Messina OD; Morales-Torres J; Emkey R; Butler PW; Yin X; Lems WF
Arthritis Rheumatol; 2019 Jul; 71(7):1174-1184. PubMed ID: 30816640
[TBL] [Abstract][Full Text] [Related]
12. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
[TBL] [Abstract][Full Text] [Related]
13. Free vitamin D correlate better with bone mineral density and thoracolumbar junction osteoporotic vertebral fractures than serum vitamin D.
Chhantyal K; He L; Mo J; Yin M; He T; Chen Y; Yang Y; Zhang L; Rong L
BMC Musculoskelet Disord; 2020 Mar; 21(1):164. PubMed ID: 32164704
[TBL] [Abstract][Full Text] [Related]
14. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.
Ringe JD; Faber H; Farahmand P; Dorst A
Rheumatol Int; 2006 Mar; 26(5):427-31. PubMed ID: 16001181
[TBL] [Abstract][Full Text] [Related]
16. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
Boonen S; Lorenc RS; Wenderoth D; Stoner KJ; Eusebio R; Orwoll ES
Bone; 2012 Sep; 51(3):383-8. PubMed ID: 22750403
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan.
Inoue D; Muraoka R; Okazaki R; Nishizawa Y; Sugimoto T
Calcif Tissue Int; 2016 Feb; 98(2):114-22. PubMed ID: 26466937
[TBL] [Abstract][Full Text] [Related]
18. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease.
Shane E; Silverberg SJ; Donovan D; Papadopoulos A; Staron RB; Addesso V; Jorgesen B; McGregor C; Schulman L
Am J Med; 1996 Sep; 101(3):262-9. PubMed ID: 8873487
[TBL] [Abstract][Full Text] [Related]
19. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
Soo I; Siffledeen J; Siminoski K; McQueen B; Fedorak RN
J Crohns Colitis; 2012 Aug; 6(7):777-86. PubMed ID: 22398088
[TBL] [Abstract][Full Text] [Related]
20. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
